Anamorelin Adverse Events: What Studies Report

What this page covers

Anamorelin has been described in the published literature as an orally active, selective agonist of the ghrelin receptor (GHS-R1a) developed for cancer anorexia-cachexia syndrome, with reviewers summarising both its appetite and anabolic effects and its tolerability profile (PMID 25945893). This page collects what published trials, systematic reviews and pharmacovigilance analyses reported about adverse events. It does not describe how the compound is used, and it is not a protocol. Readers looking for background on the ghrelin axis, trial endpoints and the development history of the molecule will find that material in PeptideU's anamorelin course; this page stays with safety findings.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a medicine, a symptom or a treatment decision.

Where the safety data came from

Most of the human adverse-event information on anamorelin comes from a small number of randomised, placebo-controlled trials in patients with advanced cancer and cachexia, plus pooled analyses of those trials. The largest contribution came from two phase 3 studies, ROMANA 1 and ROMANA 2, in which researchers randomised patients with advanced non-small-cell lung cancer and cachexia to anamorelin 100 mg orally once daily or placebo for 12 weeks (PMID 26906526). Later evidence came from systematic reviews and meta-analyses that pooled those and other randomised data (PMID 28074289), a network meta-analysis comparing pharmacotherapies for cancer cachexia (PMID 39225556), and an analysis of a national pharmacovigilance database in Japan, where the drug entered clinical use (PMID 39740881).

Two limits apply to all of this. First, the trial populations were people with advanced malignancy, so background symptoms such as nausea, fatigue and weight change overlapped heavily with the underlying disease and its treatment. Second, the controlled exposure periods were short — 12 weeks in the pivotal programme (PMID 26906526) — so long-term adverse events in other populations were not characterised by those trials.

Adverse Events in the Phase 3 Trials: What Studies Report

In the pivotal programme, the study authors reported that grade 3–4 treatment-related adverse events were infrequent and that the most notable ones were hyperglycaemia and diabetes mellitus (PMID 26906526). The same publication reported that anamorelin 100 mg once daily increased lean body mass over 12 weeks compared with placebo in both trials, while handgrip strength — the co-primary functional endpoint — did not differ significantly from placebo (PMID 26906526). That combination of findings, an anabolic signal without a measured strength benefit, shaped much of the later discussion about the drug's benefit-risk balance.

Reviews written around the same period described the phase 3 tolerability profile as generally acceptable in this frail population and grouped the reported events into metabolic effects, gastrointestinal complaints and laboratory changes rather than serious organ toxicity (PMID 28621564). A later narrative review reached a similar summary, characterising anamorelin as generally well tolerated in the trials that supported its development while flagging glucose metabolism as the main pharmacologically predictable concern (PMID 35274629).

Glucose, Insulin Resistance and Diabetes: What Studies Report

Hyperglycaemia is the adverse event most consistently attached to anamorelin in the literature, and it is mechanistically expected: ghrelin receptor agonism raises growth hormone secretion, and growth hormone reduces insulin sensitivity. In the phase 3 trials, researchers reported hyperglycaemia and diabetes mellitus among the treatment-related grade 3–4 events (PMID 26906526). A systematic review and meta-analysis of anamorelin in cancer-related anorexia/cachexia syndrome likewise reported that glucose-related adverse events were among the differences observed between anamorelin and placebo groups, while overall adverse-event rates were broadly comparable (PMID 37709824).

Reviews of the Japanese clinical experience discussed glycaemic monitoring as part of routine practice after the drug became available there, noting that patients with diabetes were a group of particular interest in post-approval discussion (PMID 37389636). A 2024 review of anamorelin for cancer anorexia-cachexia syndrome similarly summarised metabolic effects as a recurring element of the drug's reported safety profile (PMID 38771469).

Cardiac Conduction and ECG Findings: What Studies Report

The most specific post-marketing safety signal in the published literature concerns cardiac conduction. Researchers reviewed the literature and analysed the Japanese pharmacovigilance database, and reported cases of conduction defects in association with anamorelin use (PMID 39740881). That analysis was a disproportionality-style review of spontaneously reported events rather than a controlled trial, which means it can identify a signal worth investigating but cannot by itself establish how often such events occur or prove causation.

Reviews of the Japanese experience since approval also discussed cardiac considerations alongside glycaemic ones when describing how clinicians were monitoring patients receiving the drug (PMID 37389636). Earlier development-stage reviews had already noted that cardiovascular parameters were monitored in the anamorelin programme, reflecting the general regulatory attention paid to ECG effects in drugs acting on secretagogue pathways (PMID 25945893).

Gastrointestinal and General Tolerability: What Studies Report

Because anamorelin was studied in patients with advanced cancer, gastrointestinal complaints such as nausea appeared in both treatment and placebo arms. Meta-analyses that pooled randomised data reported that overall adverse-event and serious adverse-event rates did not differ meaningfully between anamorelin and placebo groups in this population (PMID 28074289). A separate systematic review and meta-analysis restricted to advanced non-small-cell lung cancer with cachexia reached a comparable conclusion about tolerability while confirming gains in body weight and lean body mass (PMID 29191597).

A 2023 systematic review and meta-analysis of efficacy and safety reported that anamorelin improved body weight, lean body mass and anorexia-related symptom scores relative to placebo, and described the safety profile as acceptable within the trials analysed (PMID 37709824). A 2024 network meta-analysis of pharmacotherapy for cancer cachexia compared several agents on both efficacy and safety endpoints and positioned anamorelin among the options with randomised evidence in this setting (PMID 39225556).

Summary of Reported Findings by Domain

Why endpoint choice shaped the safety debate

Discussion of anamorelin's risk-benefit balance has been inseparable from the question of what a cachexia or sarcopenia trial should measure. A 2025 review of trial endpoints and regulatory issues in sarcopenia and chronic illness examined how regulators have weighed body-composition changes against functional and patient-reported outcomes when assessing drugs in wasting conditions (PMID 40485364). That framing matters for safety interpretation: when a measurable benefit is confined to lean mass rather than strength, as the phase 3 data reported (PMID 26906526), even low-frequency adverse events carry more weight in regulatory assessment.

Reviews written after the phase 3 results appeared made the same point in clinical language, describing anamorelin as a candidate whose place in supportive oncology depended on how much value was attached to weight and lean-mass stabilisation in patients with advanced disease (PMID 28621564). The most recent reviews continued to frame the drug in that way while summarising its accumulated safety record (PMID 38771469).

What the literature does not establish

• Non-cancer populations. The controlled adverse-event data summarised above came from trials in patients with advanced cancer and cachexia (PMID 26906526). Comparable randomised safety data in healthy adults, athletes or people using the compound outside a medical indication are absent from the papers cited here, and that absence should be read as absence of evidence rather than evidence of safety.
• Long-term exposure. The pivotal randomised exposure was 12 weeks (PMID 26906526); multi-year controlled safety data are not described in the reviews summarised here.
• Event frequency for conduction defects. The pharmacovigilance analysis described reported cases from a spontaneous-reporting system (PMID 39740881), a design that cannot produce incidence rates.
• Interactions and comorbidity subgroups. The cited reviews discussed monitoring considerations in clinical practice (PMID 37389636) but did not provide subgroup-level randomised safety data for every comorbidity that might matter.

How to read this evidence

Three points recur across the cited papers. First, the adverse events attributed to anamorelin in randomised trials were predominantly metabolic and generally low-grade, with hyperglycaemia and diabetes mellitus named explicitly in the phase 3 report (PMID 26906526). Second, pooled analyses did not find an excess of serious adverse events versus placebo in the cancer cachexia setting (PMID 28074289, PMID 29191597). Third, post-marketing surveillance added a conduction-defect signal that the original trials were not sized to detect (PMID 39740881). Interpreting any of these findings for an individual is a clinical judgement, not something a literature summary can make.

References

• Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials (The Lancet Oncology, 2016)
• Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC (Expert Opinion on Pharmacotherapy, 2015)
• Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis (Supportive Care in Cancer, 2017)
• The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia (Future Oncology, 2017)
• Anamorelin for advanced non-small-cell lung cancer with cachexia: systematic review and meta-analysis (Lung Cancer, 2017)
• Anamorelin for cancer cachexia (Drugs of Today, 2022)
• Anamorelin in Japanese patients with cancer cachexia: an update (Current Opinion in Supportive and Palliative Care, 2023)
• The efficacy and safety of anamorelin for patients with cancer-related anorexia/cachexia syndrome: a systematic review and meta-analysis (Scientific Reports, 2023)
• Anamorelin for the Treatment of Cancer Anorexia-Cachexia Syndrome (Current Oncology Reports, 2024)
• Efficacy and safety of pharmacotherapy for cancer cachexia: a systematic review and network meta-analysis (Cancer Medicine, 2024)
• Anamorelin and Conduction Defects: A Literature Review and Analysis of the Japanese Pharmacovigilance Database (In Vivo, 2025)
• Sarcopenia in Ageing and Chronic Illness: Trial Endpoints and Regulatory Issues (Journal of Cachexia, Sarcopenia and Muscle, 2025)